Intradermal injection of tat oyi‑based therapeutic hiv vaccine reduces of 1.5 log copies/ml the hiv rna rebound median interruption in phase i/ii randomized controlled clinical trial

HIGHLIGHTS

• who: Retrovirology and collaborators from the is why these statistical data must be seen as an exploratory analysisAuthors' contributions EPL and IR conceived the clinical trial, IR was the main investigator, EPL wrote the manuscript. AD made the randomization. AD, CB, JC and JB prepared the syringes, JC and CC made the injections, EPL and EAL made ELISA test to study the Tat response. CNB made the data management. EJ and VC made statistical analyses. SM, OB and BD, oversaw the clinical trial and the manuscript. All authors read and approved the final manuscript. Author details , ETRAV . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.